SPX3,831.39+6.06 0.16%
DIA309.71-1.14 -0.37%
IXIC11,322.24+194.39 1.75%

BRIEF-Gt Biopharma Presents Preclinical Data Demonstrating Second-Generation Cd19 Targeting Tri-Specific Killer Engager Driving Robust Nk Cell Function Against B Cell Malignancies

reuters.com · 06/10/2022 08:09
BRIEF-Gt Biopharma Presents Preclinical Data Demonstrating Second-Generation Cd19 Targeting Tri-Specific Killer Engager Driving Robust Nk Cell Function Against B Cell Malignancies

- GT Biopharma Inc GTBP:

  • GT BIOPHARMA PRESENTS PRECLINICAL DATA DEMONSTRATING SECOND-GENERATION CD19 TARGETING TRI-SPECIFIC KILLER ENGAGER (TRIKE®) DRIVING ROBUST NK CELL FUNCTION AGAINST B CELL MALIGNANCIES AT EHA 2022 CONGRESS

  • GT BIOPHARMA INC - ONGOING EXPERIMENTS WILL EVALUATE FUNCTIONALITY AND EFFICACY OF GTB-7550 IN VIVO

  • GT BIOPHARMA INC - FUTURE STUDIES WILL ALSO INVOLVE ASSESSMENTS OF GTB-7550 TRIKE EFFICACY IN OTHER HEMATOLOGIC CANCERS

Source text for Eikon: ID:nGNXbFFxGl

Further company coverage: GTBP


((reuters.briefs@thomsonreuters.com;))